#### <u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

## DRAFT | June 2019

# **Materials**

Antibodies	Yes (indicate where provided: section /paragraph)	n/a
For commercial reagents, provide supplier nam e, catalogue number and RRID, if available.	/	N/A The study didn't use a ny antibodies.

Cell materials	Yes (indicate where provided: section /paragraph)	n/a
<b>Cell lines:</b> Provide species information, strain. P rovide accession number in repository <b>OR</b> supp lier name, catalog number, clone number, <b>OR</b> RRID	/	N/A The study didn't use c ell materials.
<b>Primary cultures:</b> Provide species, strain, sex of origin, genetic modification status.	/	N/A The study didn't use c ell materials.

Experimental animals	Yes (indicate where provided: section /paragraph)	n/a
<b>Laboratory animals:</b> Provide species, strain, sex, age, genetic modification status. Provide accession numb er in repository <b>OR</b> supplier name, catalog number, cl one number, <b>OR</b> RRID	/	N/A The study didn't use e xperimental animals.
Animal observed in or captured from the fiel d: Provide species, sex and age where possible	/	N/A The study didn't use e xperimental animals.
Model organisms: Provide Accession number i n repository (where relevant) OR RRID	/	N/A The study didn't use e xperimental animals.

Plants and microbes	Yes (indicate where provided: section /paragraph)	n/a
<b>Plants:</b> provide species and strain, unique accession number if available, and source (including location fo r collected wild specimens)	1	N/A The study didn't use p lants and microbes.
<b>Microbes:</b> provide species and strain, unique a ccession number if available, and source	1	N/A The study didn't use microbes.

Human research participants	Yes (indicate where provided: section	n/a

Identify authority granting ethics approval (IRB or eq uivalent committee(s), provide reference number for approval.	Page 4, line 117-121; Methods (IPFP a nd synovium samples) / paragraph 1	/
Provide statement confirming informed consent obta ined from study participants.	Page 4, line 120-121; Methods (IPFP a nd synovium samples) / paragraph 1	/
Report on age and sex for all study participants.	supplementary Table 3	/

## <u>Design</u>

Study protocol	Yes (indicate where provided: s ection/paragraph)	n/a
For clinical trials, provide the trial registration numbe r <b>OR</b> cite DOI in manuscript.	/	N/A The study is basic research.

Laboratory protocol	Yes (indicate where provided: s ection/paragraph)	n/a
Provide DOI or other citation details if detailed step-b y-step protocols are available.	/	N/A The study is basic research.

Experimental study design (statistics details)	Yes (indicate where provided: s ection/paragraph)	n/a
State whether and how the following have been don e, or if they were not carried out.		
Sample size determination	1	N/A The study is basic research.
Randomisation	/	N/A The study is basic research.
Blinding	/	N/A The study is basic research.
Inclusion/exclusion criteria	/	N/A The study is basic research.

Sample definition and in-laboratory replication	Yes (indicate where provided: s ection/paragraph)	n/a
State number of times the experiment was replicate d in laboratory	Page 6, line 198-199; Statistical a nalysis / paragraph 1	/
Define whether data describe technical or biological replicates	Page 6, line 198-199; Statistical a nalysis / paragraph 1	/

Ethics	Yes (indicate where provided: s ection/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approv al.	Page 4, line 117-121; Methods (I PFP and synovium samples) / par agraph 1	/

Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivale nt committee(s), provide reference number for appr oval.	/	N/A The study didn't use experi mental animals.
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authori ty approving study; if none were required, explain w hy.	Page 4, line 110-114; Methods (I PFP and synovium samples) / par agraph 1	/
Dual Use Research of Concern (DURC)	Yes (indicate where provided: s ection/paragraph)	n/a
If shudu is subject to due to see we see a first second set	1	N1/A

	ection/paragraph)	
If study is subject to dual use research of concern, st ate the authority granting approval and reference nu mber for the regulatory approval	/	N/A The study is not subject to d ual use research of concern.

## Analysis

Attrition Yes (indicate where provided: section/par n/a				
	agraph)	170		
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were det ermined and specified in advance.	/	N/A		
Statistics	Yes (indicate where provided: section/par agraph)	n/a		
Describe statistical tests used and justify choice of tes ts.	Page 6, line 195-197; Statistical analysis / p aragraph 1	/		
Data Availability	Yes (indicate where provided: section/par agraph)	n/a		
State whether newly created datasets are available, i ncluding protocols for access or restriction on access.	1	N/A The study didn't include newly cre ated datasets.		
If data are publicly available, provide accession numb er in repository or DOI or URL.	/	N/A The study didn't use publicly availa ble data.		
If publicly available data are reused, provide accessio n number in repository or DOI or URL, where possibl e.	/	N/A The study didn't use publicly availa ble data.		
Code Availability	Yes (indicate where provided: section/par agraph)	n/a		
For all newly generated code and software essential f or replicating the main findings of the study:				
State whether the code or software is available.	/	N/A		
If code is publicly available, provide accession numbe r in repository, or DOI or URL.	/	N/A		

## **Reporting**

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of disciplin e-specific guidelines, established and endorsed throu gh community initiatives. Journals have their own pol icy about requiring specific guidelines and recommen dations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIV E) have been followed, and whether a checklist (eg.,	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

#### DRAFT | June 2019

CONSORT, PRISMA, ARRIVE) is provided with the ma	
nuscript.	

Article information: https://dx.doi.org/10.21037/atm-21-5739